Covaxin has ability to neutralise UK strain of COVID-19-Review report

Covaxin, developed by BharatBiotech, has the ability to neutralise the UK variant of the coronavirus, according to a preprint review by bioRxiv, a free online archive and distribution service for unpublished preprints in the life sciences.

The archive is operated by Cold Spring HarborLaboratory, not-for-profit research and educational institution in New York.

Bharat Biotech performed the plaque reduction neutralisation test (PRNT50) using sera collected from the 26recipients of Covaxin and tested them against the UK variant and heterologous strain, the report said.

''A comparable neutralisation activity of sera of the vaccinated individuals showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralisation escape,'' the preprint review published in bioRxivs website said.

Covaxin is India's totally indigenous COVID-19vaccine developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

It is developed and manufactured in BharatBiotech's BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.

The vaccine is currently under Phase-3 trials and is being used as part of the nationwide immunisation programme for healthcare workers after the Central Licensing Authority granted permission for the sale or distribution of Covaxin for restricted use in emergency situations.

Reacting to the bioRxiv review, ICMR tweeted''COVAXIN developed by @BharatBiotech with @ICMRDELHI has equivalent immunogenicity against the UK-variant & circulating strains of SARS-COV-2 in India. @icmr_niv is the first in theworld to culture the UK variant.'' 

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)